Nearly a quarter of private sector employees don’t have any paid sick days, according to the National Partnership for Women & Families. Providing this benefit will save employers down the line, one expert argues.
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company plans a global Phase IIa study among children with disease, which currently lacks approved treatments.